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ABSTRACT
Objective: The treatment of the chronic hepatitis C (HCV) with α-interferon is associated 
with thyroid dysfunction (TD). The aim of this study was to evaluate thyroid function out-
come among patients with chronic HCV under treatment with conventional interferon (IFN) 
or peguilated interferon (PEG-IFN) in association with ribavirin. Patients and Methods: We 
studied 293 patients with chronic HCV, submitted to drug therapy for 24 or 48 weeks. Ini-
tially, we evaluated FT4, TSH, TPOAb, TgAb, and continued to monitor FT4 and TSH every 
three months during therapy and six months thereafter. Results: At baseline, TD prevalence 
was 6.82% (n = 20); 6.14% hypothyroidism; 0.68% hyperthyroidism. TPOAb was present in 
5.46% of euthyroid patients. Out of 273 euthyroid patients at baseline, 19% developed TD: 
17.2% hypothyroidism; 1.8% hyperthyroidism; 5.1% destructive thyroiditis (DT). 90% of 
TPOAb-positive patients at baseline developed hypothyroidism vs 14.5% of TPOAb-negative 
patients (p < 0.001). On average, TD occurred after 25.8 ± 15.5 weeks of treatment. 87.2% of 
patients who developed hypothyroidism did so during the first therapeutic cycle (p = 0.004; 
OR = 3.52; 95% CI = 1.36-9.65). Patients infected with genotype 1 virus were 2.13 times 
more likely to develop hypothyroidism (p = 0.036; 95% CI = 1.04-4.38). Hypothyroid and 
DT patients presented higher TSH levels before-treatment than patients who had remained 
euthyroid (p < 0.001; p = 0.002, respectively). DT patients presented lower qALT (p = 0.012) 
than euthyroid patients. Conclusion: Hypothyroidism was the most frequent TD, especially 
during the first cycle of α-interferon. Genotype 1 virus was associated with a risk two times 
higher for developing the illness. There was no need to interrupt or to change HCV treatment. 
Therefore, approximately 34% of TD was transient.
Keywords: hypothyroidism; hepatitis C, chronic; interferon-α.
INTRODUCTION
Hepatitis C virus (HCV) affects from 1.5% 
to 2.5% of the Western population, and is 
the most common source of infections 
transmitted by blood transfusions. HCV 
should be diagnosed as early as possible as 
most patients without treatment develop 
hepatic cirrhosis and, eventually, hepatocel-
lular carcinoma.1 
Interferon-α (IFN-α) is a good option 
for treating HCV. The antiviral action and 
modulatory effect of the drug on the auto-
immune response may elicit a production of 
antinuclear, antithyroid antibodies, as well 
as amplification of cellular cytotoxic re-
sponse. Treatment using IFN-α and ribavi-
rin (RBV), a synthetic guanosine-nucleotide 
analog, increased remission rates from 20% 
to 40%. The therapeutic efficacy of this regi-
men can be explained by the immunomod-
ulatory and anti-inflammatory additional 
effects of RBV. Hence, this combined treat-
ment favors the development of systemic 
and organ-specific autoimmune diseases, 
such as autoimmune thyroid disease (ATD) 
and thyroid dysfunction (TD).2-4
Patients infected with HCV present 40-
42% of detectable antithyroid autoantibody 
levels; whereas in patients with hepatitis B 
virus, the index varies from 5 to 10%.4 The 
prevalence of TD in patients under IFN-α 
use ranges from 1 to 35%, possibly due to 
the lack of standardization for the routine 
screening of thyroid function evaluation in 
several studies. TD resulting from the use of 
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IFN-α presents a wide spectrum of forms and intensi-
ties, such as thyrotoxicosis in 2-3% and hypothyroidism 
in 2.4-19% of the cases.4-6 TD is frequently associated 
with the female gender and HCV-related factors.7 There 
seems to be no correlation between TD and IFN-α dos-
age; however, the duration of treatment may interfere. 
Additionally, various authors have reported that 50% of 
patients with HCV and antithyroperoxidase antibodies 
detectable prior to IFN-α treatment developed ATD vs. 
5.4% of patients with negative antibodies.5,6
Considering that ATD and TD occur frequently dur-
ing HCV therapy with IFN-α and RBV, there is a recom-
mendation of systematic evaluation for their presence 
during treatment and follow-up. Once TD is diagnosed, 
very often the treatment for HCV is unnecessarily inter-
rupted, which drastically reduces therapeutic success.6
The aim of the present study was to assess thyroid 
function at baseline and during treatment for HCV with 
standard interferon-α (IFN-α) or peguilated interferon-α 
(PEG-IFN-α) combined with RBV.
MATERIAL AND METHODS
Patients
We prospectively studied 293 patients with HCV, treated 
with a combined regimen (IFN or PEG-IFN and RBV), 
and they were followed by the Infectious Disease Service 
between 2001 and 2007. Other etiologies of chronic hepa-
titis were excluded and no patients presented hepatitis B 
or AIDS.
Thyroid function was evaluated in patients before 
treatment, every three months during treatment and 
six months after treatment. Patients who presented TD 
at baseline underwent monthly reassessment; however, 
they were excluded from the follow-up group, com-
prised by euthyroid individuals. The patients were from 
the city Campinas and region, state of São Paulo, an io-
dine sufficient area. 
Therapeutic plan
All patients were treated with IFN or PEG-IFN and RBV 
and received 1-3 therapeutic schedules. Treatment for vi-
ral genotypes 2 and 3 lasted for 24 weeks, and 48 weeks for 
genotypes 1 and 4. IFN was indicated for patients infected 
by viral genotypes 2 and 3, and PEG-IFN was the first choice 
for those with genotype 1 or a second option for those with 
genotypes 2 and 3 who had failed therapy with IFN. Patients 
weighing less than 75 kg used PEG-INF-α 2b (Peg-Intron®), 
whereas patients over 75 kg were treated with PEG-INF-α 
2a (Pegasys®). Virologic response was assessed at the end of 
treatment and 24 weeks thereafter.
A subcutaneous IFN dose of 3 MU was administrated 
three times a week. A subcutaneous PEG-IFN dose of 
180 mg was administrated once a week for Pegasys® and 
1.5 mg/kg/week for Peg-Intron®. The RBV dose varied 
from 1,000 to 1,250 mg/day. IFN/PEG-IFN/RBV dose 
was not modified by the presence of thyroid dysfunction. 
The patient was referred to the Endocrinology Service 
when thyroid dysfunction persisted for over 30 days. 
Laboratory assessment 
Chronic hepatitis C diagnosis was investigated through 
alteration of qALT (ALT of patient/ALT maximum ref-
erence values, RV ≤ 1), through the presence of anti-
HCV antibody, and was confirmed through the pres-
ence of HCV-RNA (qualitative PCR-HCV, Amplicor 2.0, 
Roche). Viral genotype was determined by Line Probe 
assay, LIPA HCV, Innogenetics, Gent, Belgium. Hepatic 
damage was evaluated by biopsy and classified accord-
ing to the recommendations of the Brazilian Society of 
Pathology.
Thyroid function was assessed by serum free T4 
(FT4, RV = 0.9-1.8 ng/dL), thyrotrophin (TSH, 
RV = 0.41-4.5 mIU/mL) (enzyme immunoassay kits, 
GenBio, San Diego, USA). ATD was verified by 
the detection of serum antithyroperoxidase (TPOAb, 
RV > 76 IU/mL) and antithyroglobulin antibodies 
(TgAb, RV > 120 IU/mL) (fluorimetric enzyme immu-
noassay, Dade Behring Inc., Miami-FL, USA). 
Thyroid disorders
The following thyroid disorders were considered: 
• autoimmune thyroid disease: clinical and laboratory 
 euthyroid patients presenting elevated serum levels of
 TPOAb and/or TgAb; 
• subclinical primary hypothyroidism: increased serum 
 TSH levels, less than 10 mUI/mL with normal FT4 levels; 
• evident primary hypothyroidism: increased serum TSH 
 levels with reduced FT4 levels; 
• hyperthyroidism: increased FT4 with reduced levels 
 of TSH; 
• destructive thyroiditis: transient TD auto-limited. 
 Initial phase of thyrotoxicosis, intermediate phase of 
 hypothyroidism and resolution phase of euthyroidism 
 or permanent primary hypothyroidism.
Thyroid disorders were classified as transient or de-
finitive, depending on whether or not they returned to 
normal levels after hepatitis treatment withdrawal. Au-
toimmune etiology was based on the presence of elevat-
ed serum levels of TPOAb and/or TgAb.
Statistical analysis
The sample profile was described by frequency tables of 
the categorical variables (age, gender, qALT, viral geno-
type, presence of cirrhosis, liver biopsy, therapeutic regi-
men, type of INF-α used, total treatment time, event time 
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during treatment, sustained virological response, demon-
strating the values of absolute (n) and percentage (%) fre-
quency. Continuous descriptive variables are presented 
as mean, standard deviation, minimum, maximum and 
median values. The association between two categorical 
variables was analyzed by either Chi-square or Fisher’s 
test. The Mann-Whitney test was used to compare nu-
merical variables between patients with and without 
thyroid dysfunction. The significance level was set at 5% 
(p < 0.05). Statistical analyses were performed using the 
SAS system for Windows (Statistical Analysis System) ver-
sion 8.02. SAS Institute INC, 1999-2001, Cary, NC, USA.
RESULTS
Out of 293 patients included in the study, we verified TD 
prior to the use of IFN in 20 (6.82%); 18 of them present-
ed primary hypothyroidism (prevalence = 6.14%) and 
two, hyperthyroidism (prevalence = 0.68%) (Table 1). 
Elevated serum TPOAb levels were detected in 13 
(5.46%), and TgAb in five (1.68%) of 238 patients. 
After excluding patients with previous TD, we stud-
ied 273 euthyroid individuals who were treated with 
Interferon-α and ribavirin. Table 2 describes the base-
line characteristics of the euthyroid study patients 
prior to treatment. Under treatment, 19% (n = 52) de-
veloped TD, 18% of the men and 27% of the women 
(p = 0.104). TD was diagnosed 25.8 ± 15.5 weeks 
after treatment initiation. Hypothyroidism was verified 
in 17.2% (n = 47); hyperthyroidism in 1.8% (n = 5), and 
5.1% (n = 14) presented destructive thyroiditis (DT). 
Table 1. Baseline characteristics of patients with 
chronic hepatitis C and thyroid dysfunction before 
treatment with IFN-α
Patients           
Hypothyroidism    Hyperthyroidism
 
(n = 20)
n  18 2
Gender  
	 Female	 6/92	(6.5%)	 0 
 Male  12/236 (5.1%) 2
Age  47.9 ± 9.6 36.5 
(years)  (median = 46)
TPOAb	 	 5/15	(33%)	 0
TgAb	 	 1/16	(6.25%)	 0
Sustained virological 
response 
	 Yes	 	 8	(44.4%)	 0 
	 No	 	 10	(55.6%)	 1/1
Virus C genotype 
 1  12 (66.7%) 1 
	 2	 	 1	(5.5%)	 0 
 3  5 (27.8%) 1
Table 2. Baseline characteristics of euthyroid  
patients with chronic hepatitis C before treatment 
with IFN-α
 Patients (n total = 273)
Female  74 (27.1%)
Male  199 (72.9%)
Age (years)  43.9 ± 9.7 (18-71)
qALT	 	 2.49	±	1.7	(0.3-13.7)
Cirrhosis  
 Yes  46 (17.3%) 
	 No	 	 220	(82.7%)
Liver biopsy   
 Structural alterations   
	 	 0/1	 	 37	(14.6%) 
	 	 2	 	 120	(47.4%) 
  3  61 (24.1%) 
  4  35 (13.8%)
 Activity   
	 	 0/1	 	 17	(13.2%) 
  2  67 (51.9%) 
  3  45 (34.9%)
Virus C genotype 
 1  151 (57.8%) 
 2  7 (2.7%) 
	 3	 	 103	(39.4%)
Number of therapeutic regimens 
 1  177 (64.8%) 
	 ≥	2	 	 96	(35.2%)
Treatment duration 
 < 48 weeks  123 (45.2%) 
	 ≥	48	weeks	 	 149	(54.8%)
Total treatment duration 
37.7	±	14.0	(8-120)	
 
(weeks)
Interferon used 
 IFN  194 
 PEG  165
End of treatment response 
 Yes  184 (68.4%) 
 No  85 (31.6%)
Sustained virological response 
 Yes  144 (54.7%) 
 No  119 (45.2%)
Free T4	(ng/dL)	 	 1.21	±	0.19
TSH	(mIU/L)	 	 1.93	±	0.89
TPOAb	>	76	IU/ml	(total	n	=200)	 8	(4.0%)
TgAb	>	120	IU/mL	(total	n	=	199)	 3	(1.5%)
FT4,	RV	=	0.9-1.8	ng/dL	TSH,	RV	=	0.41–4.5	mIU/L.	
TPOAb	(RV	≤	76	IU/mL)	TgAb,	RV	≤	120	IU/mL.
Among the 13 patients presenting high TPOAb 
levels before using INF-α, five had a previous diag-
nosis of primary hypothyroidism. During the first 
therapeutic regimen, seven out of eight euthyroid 
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patients became hypothyroid. Therefore, 90% of 
TPOAb-positive patients before treatment developed 
hypothyroidism vs. 14.5% of TPOAb-negative patients 
(p < 0.001). Moreover, 10 patients were infected with 
genotype 1 virus (76.9%); one patient with genotype 2 
virus; and one with genotype 3 (one patient did not have 
the genotype identified).
Table 3 lists the characteristics of patients who 
developed hypothyroidism under treatment. 87.2% 
of the patients presented hypothyroidism during 
the first therapeutic regimen (p = 0.004; OR = 3.52; 
95% CI = 1.36-9.65). The logistic regression analysis 
related to categorical variables established that patients 
infected with genotype 1 virus were 2.13 times more 
likely to develop primary hypothyroidism (p = 0.036; 
95% CI = 1.04-4.38) during treatment. The variables age 
(p = 0.326), gender (p = 0.197), presence of cirrhosis 
(p = 0.984), liver biopsy characteristics (structural al-
terations, p = 0.498 and activity, p = 0.892), use of IFN 
(p = 0.755) or PEG-IFN (p = 0.153), type of PEG-IFN used 
(p = 0.766) and sustained virological response (p = 0.946) 
were not significantly associated with TD. 
Regarding patients under treatment, the euthyroid 
group had higher TSH serum levels before treatment 
(mean = 1.78 vs. 2.59; median = 1.6 vs. 2.72, p < 0.001) 
than the group that developed hypothyroidism. There 
was no significant difference between the two groups in 
relation to age (p = 0.567), weight (p = 0.148), FT4 lev-
els before treatment (p = 0.126) and qALT (p = 0.219). 
Table 4 describes the types of TD encountered in this 
study.
Hyperthyroidism was confirmed in a small number 
of patients (n = 5), allowing only for descriptive analysis 
(Table 5).
Table 6 describes characteristics of the 14 patients 
who triggered DT during treatment. Comparing to 
those without such complication, DT patients were not 
significantly different in terms of age (p = 0.334), weight 
(p = 0.372), gender (p = 0.755), presence of cirrhosis 
(p = 1.000), liver biopsy characteristics (structur-
al alterations, p = 0.701 and activity, p = 0.239), use 
of IFN (p = 0.765) or PEG-IFN (p = 0.147), type of 
PEG-IFN used (p = 0.510), sustained virological response 
(p = 0.823) and viral genotype (p = 0.082). 
The comparative analysis of continuous variables 
between the euthyroid group and the DT group of pa-
tients under treatment, demonstrated that the latter pre-
sented TSH levels significantly higher before treatment 
(mean = 1.78 vs. 2.55; median = 1.6 vs. 2.72, p = 0.002), as 
well as lower qALT (mean = 1.68, median = 2.10 vs. 1.35, 
p = 0.012). The comparison between the two groups 
regarding age (p = 0.096), weight (p = 0.372), and FT4 
levels prior to treatment (p = 0.727) was not significant.
Table 4. Length and intensity of thyroid dysfunction
 Hypothyroidism Hyperthyroidism  
 (n = 47) (n = 5)
Transient	 17	(36.2%)	 1	(20%)
Definitive	 30	(63.8%)	 4	(80%)
Subclinical	 20	(42.5%)	 3	(60%)
Manifest	 27	(57.5%)	 2	(40%)
Table 3. Characteristics of patients who developed 
primary hypothyroidism under IFN-α treatment
                            Hypothyroid (n = 47)
Female	 16	(34.0%)
Male	 31	(66.0%)
Age (years) 44.6 ± 9.3 (25-68)
qALT	 2.35	±	1.61	(0.7-7.6)
Cirrhosis 
	 Yes	 8	(17.0%) 
	 No	 39	(83.0%)
Liver biopsy  
 Structural alterations 
	 	 0/1	 4	(8.5%) 
	 	 2	 20	(42.5%) 
  3 14 (29.8%) 
  4 7 (14.9%)
Virus C genotype (n = 253)  
 1 31 (72.1%) 
 2/3 12 (27.9%)
Event time under  
26.52 ± 16.49 (8-96, median = 24)
 
treatment (weeks)
Number of therapeutic 
regimens at the event 
 1 41 (87.2%) 
 2 6 (12.8%)
Total treatment 
43.02	±	15.64	(24-96;	median	=	48)	
 
duration (weeks) 
Interferon used 
 IFN 14 (29.8%) 
 PEG 13 (27.6%) 
	 IFN+PEG	 20	(42.5%)
Final virological response 
 Yes 31 (68.9%) 
 No 14 (31.1%)
Sustained virological 
response (n = 254) 
 Yes 26 (57.8%) 
 No 19 (42.2%)
Free	T4	(ng/dL)	 0.79	±	0.38	(0.04-1.6;	median	=	0.80)
TSH	(mIU/L)	 27.5	±	30.5	(4.7-100.0;	median	=	9.48)
FT4,	RV	=	0.9-1.8	ng%	TSH,	RV	=	0.41–4.5	mIU/L.	
Virus C genotype predisposes to primary hypothyroidism
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DISCUSSION 
Hepatitis C virus is a hepatotropic and lymphotropic RNA 
virus which may be associated with chronic infectious dis-
ease.8 Although hepatocytes are the major site of HCV rep-
lication, extrahepatic complications of HCV infection may 
occur, such as autoimmune diseases and lymphoprolifera-
tive disorders.9
HCV treatment with IFN-α and RBV can trigger adverse 
effects frequently leading to a reduction of the dose in over 
40% of the patients or even withdrawal in approximately 14%.8
Standard or PEG-IFN-α may lead to influenza-like 
symptoms at the onset of treatment, as well as psychiatric, 
hematologic (neutropenia and thrombocytopenia)10,11 and 
thyroid dysfunction.12 As referred by Sachithanandan et al.,13 
thyropathies affect 26.3% of HCV treated patients. The as-
sociation with RBV usually induces hemolytic anemia, with 
no additional risk of thyropathy.10
Generally, SVR is achieved in approximately 60% of 
the patients, 40% among patients of viral genotype 1 and 
76% among those with viral genotypes 2 and 3. Other SVR 
predictive factors include: age less than 40 years, weight 
lower than 75 kg, female gender, Caucasian race, low vi-
ral load before treatment, and absence of liver cirrhosis.10 
In our study, HCV patients obtained 53.9% as response 
rate of IFN-α therapy, in accordance to the literature. The 
study population showed a predominance of Caucasoid 
male patients infected by virus C of genotypes 1 and 3.
Table 6. Patients who developed destructive  
thyroiditis under IFN-α treatment
Patients (n = 14)
Female  4 (28.5%)
Male	 	 	 10	(71.5%)
Age	(years)	 	 40.0	±	8.0	(30-60)
qALT	 	 	1.68	±	1.10	(0.8-6.6;	median	=	1.3)
Cirrhosis  
 Yes   2 (14.3%) 
 No   12 (87.7%)
Liver biopsy 
 Structural alterations 
	 	 0/1	 	 3	(23.0%) 
  2  5 (38.5%) 
	 	 3	 	 4	(30.7%) 
  4  1 (7.6%)
Virus C genotype 
 1   11 (78.5%)* 
 2/3   3 (21.4%)
Event time under   
19.60	±	8.99	(8-32,	median	=	18)
 
treatment (weeks)
Number of therapeutic 
regimens at the event 
 1   13 (92.8%) 
 2   1 (7.4%)
Total treatment  
42.86	±	10.22	(24-48;	median	=	48)
 
duration (weeks) 
Interferon used 
 IFN   8 (57.1%) 
 PEG  6 (42.8%)
Sustained virological 
response 
 Yes   8 (57.1%) 
 No   6 (42.8%)
Outcome 
	 Hypothyroidism	 	 10	(71.5%) 
 Euthyroidism  4 (28.5%)
Table 5. Patients who developed hyperthyroidism 
under IFN-α treatment
Hyperthyroidism (n = 5)
Female	 3	(60%)
Male	 	 2	(40%)
Age (years) 46.4 ± 7.3 (39-56)
qALT	 	 1.82	±	0.94	(1.3-3.5;	median	=	1.4)
Cirrhosis  
	 Yes		 1	(20%) 
	 No	 	 4	(80%)
Liver biopsy 
 Structural alterations 
	 	 0/1	 0	(0%) 
	 	 2	 3	(60%) 
	 	 3	 1	(20%) 
	 	 4	 1	(20%)
Virus C genotype 
	 1	 	 2	(50%) 
	 2/3		 2	(50%)
Event time under  
19.60	±	8.99	(8-32,	median	=	18)
 
treatment (weeks)
Number of therapeutic 
regimens at the event 
	 1	 	 5	(100%)
Total treatment 
43.2	±	10.73	(24-48;	median	=	48)
 
duration (weeks) 
Interferon used 
	 IFN		 4	(80%) 
	 PEG	 1	(20%)
Sustained virological 
response 
	 Yes		 4	(80%) 
	 No	 	 1	(20%)
Free	T4	(ng/dL)	 2.57	±	1.56	(1.36-4.46;	median	=	1.50)
TSH	(mIU/L)	 0.13	±	0.17	(0.01-0.33;	median	=	0.1)
FT4,	RV	=	0.9-1.8	ng%	TSH,	RV	=	0.41–4.5	mIU/L.	
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Based on the literature,2 standard IFN was indicated 
for patients infected with virus of genotypes 2 and 3, 
and PEG-IFN was the first choice for genotype 1. Non-
responding patients with genotypes 2 and 3 could then 
be treated with PEG-IFN. More than one therapeutic 
regimen was prescribed to 35.2% of the patients, and 
54.8% of them were treated for 48 weeks. PEG-IFN 
was administrated to 165 patients: those who weighed 
less than 75 kg used PEG–IFN-α 2b and those with 
more than 75 kg, PEG–IFN-α 2a. 
Firstly, Pateron et al.14 reported a prevalence of 14% of 
antithyroid autoantibodies in HCV patients. A review 
of published controlled studies15 observed that most reports 
confirmed a higher prevalence of autoimmune thyroid dis-
ease and hypothyroidism in chronic HCV-infected patients. 
Several studies found that female gender and the pres-
ence of TPOAb were considered major risk factors for the 
development of hypothyroidism.16-19 Our data demonstrated 
that TPOAb-positive patients had a higher chance of de-
veloping hypothyroidism; however, females were not more 
prone, similarly to the findings reported by Muratori et al.20 
and Stefanova-Petrova et al.21 
The prevalence of hypothyroidism in HCV patients is 
approximately 9% (0-13%) vs. 3% (0.5-4%) in healthy sub-
jects.19,22-24 Thyroid autoimmunity was demonstrated in 15% 
(5-28%) of the HCV patients and in 12% (0-11%) of healthy 
subjects, indicating a slight though significantly higher 
risk.15 In our study, we verified that the prevalence of hypo-
thyroidism (6.1%) and thyroid autoimmunity (5.5%) found 
in HCV patients before treatment was similar to the litera-
ture reports, in spite of the differences existing in geographi-
cal distribution, genetic variability, iodine intake or other 
infectious agents.25,26 Moreover, the prevalence of hyperthy-
roidism before IFN-α treatment (0.68%) found in our study 
population was not significantly different in HCV-infected 
patients, as described in the literature.15
After IFN-α therapy, 19% presented thyroid dysfunction: 
hypothyroidism in 17.2%, hyperthyroidism in 1.8% and 
destructive thyroiditis in 5.1% – very similar values were 
found by Sachithanandan et al.13 (26.3%), higher than those 
described by Moncoucy et al.27 (7%) and Tran et al.16 (6.7%). 
The rates of thyroid dysfunction triggered by the two 
types of IFN-α, standard and peguilated, were similar, as 
also found by Moncoucy et al.27 Moreover, thyroid dysfunc-
tion was not associated with sustained virological response 
of chronic hepatitis C to IFN-α therapy, as also demonstrat-
ed by Hsieh et al.28 and in contrast to previous reports.29-31 
In our patients, the presence of thyroid dysfunction did not 
lead to changes in the dose or therapy withdrawal.
After IFN-α plus RBV treatment 17.2% developed pri-
mary hypothyroidism. However, this rate has varied in sev-
eral studies.16,27 Among risk factors evaluated: age, gender, 
presence of cirrhosis, qALT and FT4 levels before treatment, 
type and commercial presentation of IFN-α used, and SVR, 
we found no association with primary hypothyroidism. In 
contrast, the likelihood of developing primary hypothyroid-
ism increased in the presence of TPOAb, genotype 1, to be 
on the first therapeutic regimen, and having higher TSH lev-
els before treatment. This last finding was also observed by 
Antonelli et al.19 
Detection of TPOAb before therapy was associated 
with a risk 3.5 times greater of becoming hypothyroid on 
IFN-α use; 90% of such patients in our study developed 
the dysfunction vs. 14.5% of TPOAb-negative, corrobo-
rating Prummel and Laurberg,7 who found a relative risk 
of 3.9. Elevated endogenous interferon in response to 
viral diseases could possibly be associated with the de-
velopment of IFN-α induced thyroiditis by in genetically 
predisposed individuals.17,27,32-34
Prummel and Laurberg7 have demonstrated that the 
female gender has a relative risk of 4.4 for developing au-
toimmune thyroiditis. This strong preponderance may 
perhaps be due to the effects of estrogen or secondary to 
X chromosome susceptibility genes.35,36 This fact was not 
corroborated by our study, as well as by Muratori et al.20 
and Stefanova-Petrova et al.21 It is important to highlight 
that thyroid dysfunction could result from a direct effect 
of IFN-α on thyroid cell function.28,37,38
The higher prevalence of virus C genotype 1 in patients 
who developed hypothyroidism is not a consensus in the 
literature. Sachithanandan et al.13 have detected elevated 
TPOAb levels before and during therapy only in geno-
type 1 patients. Conversely, Huang et al.34 observed higher 
prevalence of genotype 1b/2b in women with hepatitis C 
and detectable TPOAb, but with no correlation with hypo-
thyroidism. Viral replication results in the production of 
a heterogeneous viral population within an infected indi-
vidual.39 Some authors suggested that a portion of the HCV 
genome could share a partial sequence homology in a few 
amino acid segments with thyroglobulin and microsome, 
rendering HCV patients susceptible to autoimmune thy-
roid diseases.28 This hypothesis could explain the relation 
between viral genotype and the predisposition to develop 
thyroid diseases in patients infected by virus C genotype 1, 
as verified in our patient population.
In the present study, patients had a relative risk of 3.5 
for developing hypothyroidism during the first treatment 
course; however, Moncoucy et al.27 found no difference in 
thyroid dysfunction rate between first and second courses 
of treatment. Previous studies have reported that thyroid 
dysfunction induced by IFN-α could develop in the first 
week or after a few months, during and after therapy, with 
a possible contribution of cumulative dose.17,29,32 Never-
theless, the underlying mechanism remains unclear. 
The immunomodulatory action of IFN-α in suscepti-
ble patients38,40-42 could affect the thyroid hormone syn-
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thesis and secretion in vitro.43 Our data did not suggest 
a cumulative dose-effect, as only a few patients did not 
present thyroid dysfunction during the first treatment. 
Interestingly, after drug withdrawal, 64% of the patients 
remained hypothyroid, requiring L-thyroxin replacement 
therapy, and the other patients presented the subclinical 
form of the disease.
Hyperthyroidism seems a rare event during IFN-α ther-
apy and was verified in 1.8% of the patients. Several studies 
found even lower prevalence of hyperthyroidism, ranging 
from 0.9% to 1.1%.16,27,29,44
Destructive thyroiditis occurred in 5.1% of our patients 
and approximately 70% developed permanent hypothyroid-
ism. Almost 50% of non-autoimmune IFN-α-induced thy-
roiditis manifests such a destructive thyroiditis, a self-lim-
ited inflammatory disorder characterized by three phases of 
six to eight weeks each: thyrotoxicosis, hypothyroidism and 
resolution to euthyroidism or definitive hypothyroidism in 
less than 5% of the cases. The symptoms are usually mild, 
probably leading to a lower diagnostic rate; however, atrial 
fibrillation may occur.8,45 We observed that TSH levels before 
treatment were higher and qALT was lower in patients who 
developed destructive thyroiditis under IFN-α. This finding 
has not been previously reported in the literature. Some au-
thors found recurrent thyroiditis during retreatment;46 how-
ever, in our study, 98% of the patients developed destructive 
thyroiditis only during the first treatment.
We concluded that in the screening for predictive factors 
of thyroid dysfunction in HCV patients before treatment 
with IFN-α it is especially important to evaluate TSH levels, 
as well as antithyroid antibodies and viral genotype. More-
over, the first contact with IFN-α holds substantial risk to 
develop thyroid dysfunction. Special care is essential when 
there are laboratory alterations indicating thyrotoxicosis, 
which may be signaling an initial phase of destructive thy-
roiditis, a benign and self-limited disturbance. We empha-
size that a significant part of the dysfunction was transient 
or subclinical, not requiring treatment. 
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